Literature DB >> 27289076

Patient-reported outcome measures for allergy and asthma in children.

Ireneous N Soyiri1, Bright I Nwaru1,2, Aziz Sheikh1.   

Abstract

There is increasing recognition of the importance of patient's perceptions of disease and their assessments of heathcare processes. Patient-reported outcome measures (PROMs) are therefore now regarded as at least as important as the traditional objective measures of disease. For minors, parental and, except in the very young and severally cognitively impaired, the child's perspectives are important because they provide unique and complementary information. In this review, we summarize the evidence on PROMs for allergy and asthma for use in children. Overall, there are fewer PROMs available for use in children than in adults. We were able to identify some validated pediatric PROMs that have been developed for use in atopic eczema/dermatitis, food allergy, allergic rhinitis/rhinoconjunctivitis, and asthma. There is very limited evidence on deploying these instruments out with research settings. There is therefore a pressing need to report on the experiences of using PROMs for allergy and asthma in routine clinical care. In particular, there is a need to understand how acceptable these are to children/carers, whether they can be incorporated into routine clinical assessments and if they are responsive to changes in treatment made in routine clinical practice.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Allergy; Asthma; Children; Clinical assessment; PROMs; Patient-reported outcome measures

Mesh:

Year:  2016        PMID: 27289076     DOI: 10.1111/pai.12603

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  4 in total

Review 1.  Is It Time for a Patient-Centered Quality Measure of Asthma Control?

Authors:  Elizabeth Herman; Suzanne Beavers; Ben Hamlin; Kaytna Thaker
Journal:  J Allergy Clin Immunol Pract       Date:  2019-04-04

Review 2.  Opportunities and challenges of incorporating clinical outcome assessments in brain tumor clinical trials.

Authors:  Emanuela Molinari; Tito R Mendoza; Mark R Gilbert
Journal:  Neurooncol Pract       Date:  2018-08-07

Review 3.  Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project.

Authors:  M A Calderon; P Demoly; T Casale; C A Akdis; C Bachert; M Bewick; B M Bilò; B Bohle; S Bonini; A Bush; D P Caimmi; G W Canonica; V Cardona; A M Chiriac; L Cox; A Custovic; F De Blay; P Devillier; A Didier; G Di Lorenzo; G Du Toit; S R Durham; P Eng; A Fiocchi; A T Fox; R Gerth van Wijk; R M Gomez; T Haathela; S Halken; P W Hellings; L Jacobsen; J Just; L K Tanno; J Kleine-Tebbe; L Klimek; E F Knol; P Kuna; D E Larenas-Linnemann; A Linneberg; M Matricardi; H J Malling; R Moesges; J Mullol; A Muraro; N Papadopoulos; G Passalacqua; E Pastorello; O Pfaar; D Price; P Rodriguez Del Rio; R Ruëff; B Samolinski; G K Scadding; G Senti; M H Shamji; A Sheikh; J C Sisul; D Sole; G J Sturm; A Tabar; R Van Ree; M T Ventura; C Vidal; E M Varga; M Worm; T Zuberbier; J Bousquet
Journal:  Clin Transl Allergy       Date:  2016-11-23       Impact factor: 5.871

Review 4.  Measuring the Impact of Food Immunotherapy on Health-Related Quality of Life in Clinical Trials.

Authors:  Melanie Lloyd; Audrey Dunn Galvin; Mimi L K Tang
Journal:  Front Allergy       Date:  2022-07-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.